Methylation-specific qPCR for the EBV C promoter to quantify EBV methylation

Area of Science:

• Virology
• Molecular Biology
• Cancer Research

Background:

• Epstein-Barr Virus (EBV) is linked to various diseases, including cancers.
• EBV C promoter methylation is observed in EBV-associated malignancies but not in free virion DNA.
• Quantifying EBV methylation is crucial for understanding disease pathogenesis.

Purpose of the Study:

• To develop and evaluate a methylation-specific PCR assay for the EBV C Promoter (MSPCP).
• To quantify EBV methylation in human biological specimens.
• To assess the utility of MSPCP in research and clinical settings.

Main Methods:

• Designed methylation-specific primers targeting CpGs in the EBV C Promoter.
• Evaluated MSPCP using synthetic oligonucleotides, cell lines, virion DNA, and clinical specimens.
• Validated MSPCP results with orthogonal methods.

Main Results:

• MSPCP demonstrated a linear range of 0-100% methylation in contrived samples.
• High-level EBV C promoter methylation (94-100%) was detected in EBV-associated tumors.
• High-level EBV methylation was found in plasma of Hodgkin lymphoma patients, but not in saliva from healthy individuals.

Conclusions:

• MSPCP is a simple, rapid, and accurate method for assessing EBV C promoter methylation status.
• This assay can differentiate between pathogenic and non-pathogenic EBV methylation.
• MSPCP holds potential for diverse research and clinical applications.